Evonik offers formulation services to develop long-acting injectables (LAIs) designed to release small molecules, peptides, proteins and nucleic acids for weeks and months. Both systemic and local drug delivery can be achieved. Evonik’s LAIs are market proven microparticle and implant dosage forms that comprise biocompatible, bioabsorbable RESOMER® & LACTEL® polymers, established lactide/glycolide polymers that have a long safety record as shown from their use in 60+ drug delivery products.
Typical Applications
Long-Acting Injectable PLG drug products are the dominant polymer platform for controlled-release parenteral medications. They are primarily used to treat chronic diseases requiring long-term adherence, providing stable drug delivery over weeks to months and eliminating the need for daily oral dosing.
Typical clinical and therapeutic applications include:
Typical clinical and therapeutic applications include:
- Psychiatric and neurodegenerative disorders
- Substance abuse disorders
- Oncology and hormonal therapies
- Diabeties and metobolic diseases
- Localized pain and inflammation management
- Opthalmology
Benefits at a glance
- Experience: Evonik's formulation experience and drug delivery technologies from providing formulation services and innovation for 50+ years.
- Proven: Market-tested microparticle and implant dosage forms.
- Versatile: Enables both systemic and local drug delivery.
- Safe: Uses biocompatible, bioabsorbable RESOMER® and LACTEL® polymers.
- Trusted: Lactide/glycolide polymers are used in 60+ approved products.